Article: The Role of the Pharma Industry in Superseding Outdated Medical Practices
There has been and continues to be a surge in biotech innovation. But a pertinent question arises: how frequently are older, now outdated technologies phased out? Precision’s Ross Maclean, Phil Cyr and Ray Roth discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.
Webinar: NICE Early Scientific Advice: When, Why, and How!
Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it?
Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.
Article: Innovation in Gene Therapies
Despite innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought into focus the need for even more advancement in the field. In this Pharma Live article Precision’s Phil Cyr discusses some of the innovations that are occurring to address these issues.
White Paper: Moving CGTx Clinical Development Forward in 2023
Clinical trials are foundational to developing innovative, life-saving treatments and cures for patients. For developers of cell and gene therapy (CGTx) products, the path to clinical success is fraught with vast and complex challenges. The CGTx field is becoming more crowded, with increased clinical trial volume and an influx of less-experienced sponsors contributing to an increase in clinical holds in the category. Such challenges intensify the pressure to succeed in a fiercely competitive environment.
White Paper: Market Trends and Expectations for Advanced Therapies in 2023
The cell and gene therapy space has undergone transformational change in the last few years, driven by the promise these modalities have demonstrated in addressing rare and intractable diseases. Achievements in the CAR-T therapy space – there are now six approved CAR-T treatments on the market – in conjunction with breakthroughs in gene therapy and viral vector drugs, have signaled a new era of innovation aimed at furthering cell and gene therapies within the greater healthcare landscape.
This white paper is based on a panel discussion hosted by Precision ADVANCE, experts from across the cell and gene therapy sector convened to explore the ways their organizations have met headlong the challenges and opportunities that typify cell and gene therapy development. Panelists for the event included:
- Andy Kinley, Vice President, Innovation and Clinical Science, Precision for Medicine
- Peter Andersen, Chief Scientific Officer, Vita Therapeutics
- Deborah Phippard, Chief Scientific Officer, Precision for Medicine
- Palani Palaniappan, Chief Technology Officer, Pioneering Medicines, Flagship Pioneering
- Phil Cyr, Senior Vice President, Precision Value & Health
- Charlie Harper, Vice President, Project Farma
White Paper: Gene Editing Breakthroughs: A New Hope for Patients
Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.
In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.
Three PRECISION agencies are ranked in MM+M’s Top 100 North American healthcare agencies of 2023
Three Precision agencies – PRECISIONvalue, PRECISIONeffect and PRECISIONscientia – each rank as one of MM+M’s Top 100 North American healthcare agencies of 2023.
Conference: 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit
Precision will be at this year’s 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit, June 20-21, 2023, in Vienna, Austria. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the development for cell and gene therapies.
Connect with our Advanced Therapy experts!
- Schedule a meeting with one our our experts
- Be sure to attend Precision’s own, Houria Bachtarzi’s presentation on June 20, 2023, at 10:10 AM CEST
You can register for the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit below:
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Event: Cell & Gene Reception @ BIO, 2023
Precision is honored to be a co-host of this year’s ARM Cell & Gene Reception @ BIO, May 5, 2023, in Boston, MA. Attendees will enjoy extensive networking opportunities with the sector’s top decision makers including executives from leading companies located in the Boston area!
Connect with our Advanced Therapy experts!
- Date: Monday, June 5, 2023
- Time: 6:00pm – 9:00pm ET
- Location: Woods Hill Pier 4, Boston, MA
Registration is complimentary – CLICK HERE to reserve your spot.